GlobeNewswire

Leonhardt Ventures Announces Issuance of Pioneering U.S. Patent for Multi-Modality Customized Bioelectric Treatment of Cancer

Leonhardt Ventures LLC
6 min read
Leonhardt Ventures Announces Issuance of Pioneering U.S. Patent for Multi-Modality Customized Bioelectric Treatment of Cancer
Leonhardt Ventures Announces Issuance of Pioneering U.S. Patent for Multi-Modality Customized Bioelectric Treatment of Cancer


Mission Viejo, California, United States, Dec. 22, 2021 (GLOBE NEWSWIRE) -- Leonhardt Ventures LLC, a pioneer in developing bioelectric and biologic innovations for organ regeneration and healing, today announced that the U.S. Patent and Trademark Office issued a pioneering U.S. patent for its novel multi-modality bioelectric stimulation system for treating cancer.

This technology is exclusively licensed to CancerCell LTP, a Leonhardt Ventures LLC formative stage startup Licensable Technology Platform LTP, that is currently incubating in Leonhardt's Launchpads, the company's research and development innovation incubator. CancerCell had already exclusively licensed nine U.S. patents related to the bioelectric treatment of cancer from inventor Eleanor Schuler https://cancercellinc.com/list-of-the-issued-cancer-patents/. Leonhardt Ventures has also licensed to CancerCell a series of other patents, including ones for bioelectric inflammation management related to cancer treatment and combined bioelectric and biologics treatment for organ recovery and healing designed to be utilized after cancer tumors are eradicated to aid in the full recovery of affected organs.

Issued U.S. Patent 11,185,691 https://patents.justia.com/patent/11185691 Tumor Therapy with 20 issued patent claims describes these elements:

  1. Real-time reading of bioelectric signaling and protein expressions of cancer tumors.

  2. Customized bioelectric signaling delivery based on real-time tumor reads.

  3. Specific bioelectric signaling sequences to jam communication of cancer tumors.

  4. Bioelectric signaling sequences for anti-angiogenesis protein expression to starve a tumor of blood supply.

  5. Bioelectric signaling sequences that change the surface proteins and electrical charge polarity to elicit an immune response to attack the tumors.

  6. Bioelectric signaling sequences to reprogram cancer cells to stop their spread

  7. Bioelectric signaling sequences for managing chronic inflammation and its links to cancer spread.

  8. Bioelectric signaling sequences of specific protein expressions such as klotho to suppress cancer spread and tumor growth.

  9. Bioelectric signaling sequences to regenerate an organ back to full health after cancer tumor eradication.

Howard J. Leonhardt, Executive Chairman and CEO of Leonhardt Ventures LLC and CancerCell LTP, and the primary inventor of this technology, said, "We are pleased that the U.S. Patent and Trademark Office has issued this patent that we believe to be pioneering. We have all lost loved ones to cancer. My mother, Penny, passed away from cancer in 1995 at 49 after a three-year illness. This fall, we lost Ken Evans, one of our highly-valued board directors, to cancer. The work we have undertaken for CancerCell is to honor them. Existing chemotherapy and radiation treatments are highly toxic, causing many short and long-term side effects. Treatments such as the emerging immunotherapies, while groundbreaking, only address one pathway for cancer tumor growth and have limited efficacy. Other electromagnetic therapies primarily jam communication signals and do not adequately address other issues. They are not customized for each patient in real-time as our treatment is designed to be. We hope that CancerCell treatment, as described in this patent and other patents we hold, will do a better job of not only eradicating cancer with fewer side effects but in also facilitating organ recovery and full recovery of health and quality of life and further, even reduce the risk of cancer relapse."

and

Recommended Stories